Most Read Articles
14 Sep 2019
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.
15 Sep 2019
Podcast: Dr Shamir Mehta briefly discusses the clinical impact of findings from the COMPLETE trial
16 Sep 2019
Podcast: Prof Derek Chew explains the importance of a 1-hour troponin T protocol in suspected ACS as discussed in the RAPID-TnT trial
15 Sep 2019
Sodium-glucose transport protein 2 (SGLT2) inhibitors exert a putative epigenetic regulation of the protecting cardiovascular effect, reports a study, adding that dapagliflozin may protect the kidneys by preserving renal vasodilating capacity.

A Paradigm Shift in the Assessment and Management of Atherosclerotic Cardiovascular Disease Risk

11 Sep 2019
At the recent 10th Malaysian Endocrine and Metabolic Society (MEMS) Annual Congress(MAC) held in Hilton Kuala Lumpur, Dr Wong Ming, a consultant endocrinologist from Sunway Medical Centre, spoke on the role of non–high-density lipoprotein cholesterol (non–HDL-c) as an emerging marker and treatment target for cardiovascular (CV) disease. Additionally, she also highlighted the role of fenofibrate in delaying and preventing diabetic retinopathy (DR).

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
14 Sep 2019
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.
15 Sep 2019
Podcast: Dr Shamir Mehta briefly discusses the clinical impact of findings from the COMPLETE trial
16 Sep 2019
Podcast: Prof Derek Chew explains the importance of a 1-hour troponin T protocol in suspected ACS as discussed in the RAPID-TnT trial
15 Sep 2019
Sodium-glucose transport protein 2 (SGLT2) inhibitors exert a putative epigenetic regulation of the protecting cardiovascular effect, reports a study, adding that dapagliflozin may protect the kidneys by preserving renal vasodilating capacity.